Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Neurogene Inc.

Get SEC filing alerts via email and in your feed for Neurogene Inc.

NGNE

Neurogene Inc.

About Neurogene Inc.

Neurogene Inc. is a biotechnology company focused on developing gene therapies for rare, complex neurological diseases. Utilizing proprietary EXACT transgene regulation technology and in-house manufacturing, it advances clinical-stage programs like NGN-401 for Rett syndrome and pipeline candidates for other neurodegenerative disorders. The company leverages collaborations with academic institutions, targeting unmet medical needs with innovative, scalable genetic medicines delivered via optimized routes to the central nervous system.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Neurogene Inc.

1
1
Neurogene Inc. Neurogene Reports $30.9 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Neurogene Inc. Neurogene Reports $90.4 Million Net Loss for 2025, Focuses on NGN-401 Development

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Neurogene Inc. Neurogene Reports $20.9 Million Net Loss in Q3 2025, No Revenue Generated

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Neurogene Inc. Neurogene Reports $22M Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Neurogene Inc. Neurogene Reports $22.6 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Neurogene Inc. Neurogene Inc. Reports $75.1 Million Net Loss for 2024 Amid Rising Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Neurogene Inc. Neurogene Inc. Reports Revenue Growth, Substantial Losses in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments